Earnings Watch: Margin squeeze, hiring freeze, and crisis mode Earnings Watch: Margin squeeze, hiring freeze, and crisis mode Earnings Watch: Margin squeeze, hiring freeze, and crisis mode

Earnings Watch: Margin squeeze, hiring freeze, and crisis mode

Equities 10 minutes to read
PG
Peter Garnry

Head of Equity Strategy

Summary:  Yesterday's earnings releases from H&M, Nike, and Micron added more evidence to our hypothesis that the market is underestimating the margin squeeze that is unfolding at rapid speed. The cost-of-living crisis suppressing demand and rising wages impacting input costs are a dangerous cocktail for many companies including Apple that is lowering its production of iPhones to align with the lower demand. Meta also announced a hiring freeze and potential restructurings highlighting the deteriorating environment. The Q3 earnings season will most likely be a nasty surprise for many investors and analysts, and will likely trigger downgrades and lower price targets adding the next negative dynamic to the equity market.


Warnings signs from H&M, Nike, and Micron

If investors were hoping for good earnings news yesterday ahead of the Q3 earnings season that starts in two weeks they were left disappointed, or maybe even terrified. H&M and Nike both delivered operating margins below estimates as input costs are soaring, and H&M is going as far now as introducing charging for online returns suggesting the Swedish fashion retailer is under pressure. Nike delivered a small positive surprise on revenue but missed on gross margin by 1.1%-points filtering all the way through to FY23 Q1 EPS of $0.93 vs $1.16 a year ago. But two things in Nike’s results must have terrified investors. The company’s inventory levels continued to rise sharply suggesting terrible supply chain management and the company said that it would aggressively begin to reduce inventory in the current quarter. The US sports retailer expect gross margin to decline by 3.5-4%-points in their Q2 as a result of reducing inventory at an accelerated pace.

The weak results from H&M and Nike was not a big surprise to us as we have highlighted many times on our Saxo Market Call podcast and in equity notes that the energy shock is causing a cost-of-living crisis that is severely impacting consumption. But the outlook from Micron Technology was the big shocker as the memory chip manufacturer is guidance FY23 Q1 revenue of $4-4.5bn vs est. $6bn and adjusted gross margin in their Q1 of 24-28% vs est. 33.6%. We knew about the impact from the cost-of-living crisis and the signals from memory chip manufacturers have increasingly been bad, but this slowdown is dramatic and pointing towards rapidly deteriorating demand for consumer electronics. That is also why we warned about Apple’s earnings in our equity note yesterday, and that it is likely to impact the entire market sentiment and overall Q3 earnings season.

Finally, Meta announced yesterday that it is implementing a complete hiring freeze and that restructurings are under way. The technology company is under pressure in its advertising business from the data privacy update in iOS and slowing marketing demand as companies are cutting costs. On top of that, Meta is spending $10-12bn annualized on its Metaverse which is likely insanely expensive in the current energy shock with high electricity prices and venturing into a new platform might also not be the first priority of most companies these days.

Analysts are living in an alternative earnings universe

Consensus estimates for Q3 EPS in S&P 500 are still pointing toward q/q growth and as we wrote in yesterday’s note this equates to new record profit margin when we factor in consensus estimates for revenue which is set to decline. To us things are not adding up any longer and we expect revenue to continue increasing or being flat while EPS will take a big hit reducing the net profit margin in the S&P 500 by around 1%-point to 11.7%. Rising input costs now coming from wages which is the biggest operational expense item will drastically reduce margins in the upcoming earnings season and guidance will be uncertainty and weak from many companies. This will likely lead to a lot of downgrades and as we said many times recently trigger the next negative dynamic in the equity market leading to further declines.

Next week’s earnings

The list below highlights the most important earnings releases next week. Our focus will be on earnings from Biogen and Tesco. With the excellent news three days ago from Biogen and its Japanese partner Eisai that it has a treatment that slows Alzheimer’s in a large phase 3 trial, we expect Biogen to more about the potential for this drug if it is approved in the future. The news about this Alzheimer’s treatment is generally a great news for biotechnology investors that have suffered this year, but it also underscores why biotechnology should be part of long-term investors’ portfolios. Tesco is not usually a very interesting company but its FY23 1H result (ending 31 August) good be worth watching as Tesco has a large exposure to the UK consumer and as a grocery retailer can give insights into whether inflationary pressures are beginning to ease or not.

  • Tuesday: Biogen
  • Wednesday: Keurig Dr Pepper, Aeon, Lamb Weston, Tesco, RPM International
  • Thursday: Seven & I, Conagra Brands, Constellation Brands, McCormick & Co
Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo Capital Markets HK Limited holds a Type 1 Regulated Activity (Dealing in securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged foreign exchange trading); Type 4 Regulated Activity (Advising on securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong

By clicking on certain links on this site, you are aware and agree to leave the website of Saxo Capital Markets, proceed on to the linked site managed by Saxo Group and where you will be subject to the terms of that linked site.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

Please note that the information on this site and any product and services we offer are not targeted at investors residing in the United States and Japan, and are not intended for distribution to, or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Please click here to view our full disclaimer.